Fusarium verticillioides fungemia in a liver transplantation patient: Successful treatment with voriconazole

Diagnostic Microbiology and Infectious Disease

Volumn 71, Issue 4, 2011, Pages 438-441

  Cocchi, Stefania ^a   Codeluppi, Mauro ^a   Venturelli, Claudia ^a   Bedini, Andrea ^a   Grottola, Antonella ^a   Gennari, William ^a   Cavrini, Francesca ^b   Di Benedetto, Fabrizio ^a   De Ruvo, Nicola ^a   Rumpianesi, Fabio ^a   Gerunda, Giorgio Enrico ^a   Guaraldi, Giovanni ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Disseminated Fusarium verticillioides infection; Invasive fusariosis; Liver transplantation; Systemic fusariosis; Voriconazole

Indexed keywords

AMPHOTERICIN B; CASPOFUNGIN; CYCLOSPORIN; FLUCONAZOLE; FUNGAL DNA; ITRACONAZOLE; PREDNISONE; VORICONAZOLE;

ADULT; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BLOOD CULTURE; CASE REPORT; CONIDIUM; CONTROLLED STUDY; DNA SEQUENCE; DRUG EFFICACY; ERYTHEMA; FEMALE; FEVER; FUNGEMIA; FUNGUS CULTURE; FUNGUS HYPHAE; FUSARIOSIS; FUSARIUM MONILIFORME; GRAFT RECIPIENT; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; LEG PAIN; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; LOADING DRUG DOSE; MYCELIUM; NONHUMAN; PAPULE; PRIORITY JOURNAL; RETRANSPLANTATION; SKIN BIOPSY; SKIN DEFECT;

ADULT; ANTIFUNGAL AGENTS; FEMALE; FUNGEMIA; FUSARIOSIS; FUSARIUM; HUMANS; IMMUNOCOMPROMISED HOST; LIVER TRANSPLANTATION; PYRIMIDINES; TREATMENT OUTCOME; TRIAZOLES;

EID: 82555165184     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2011.08.024     Document Type: Article

References (20)

1. Baden L.R., Katz J.T., Fishman J.A., Koziol C., DelVecchio A., Doran M., Rubin R.H. Salvage therapy with voriconazole for invasive fungal infections in patients failing or intolerant to standard antifungal therapy. Transplantation 2003, 76:1632-1637.
2. Bezuidenhout C.C., Prinsloo M., Van der Walt A.M. Multiplex PCR-based detection of potential fumonisin-producing Fusarium in traditional African vegetables. Environ. Toxicol. 2006, 21:360-366.
3. Boutati E.I., Anaissie E.J. Fusarium, a significant emerging pathogen in patients with hematologic malignancy: ten years' experience at a cancer center and implications for management. Blood 1997, 90:999-1008.
4. Campo M., Lewis R.E., Kontoyiannis D.P. Invasive fusariosis in patients with hematologic malignancies at a cancer center: 1998-2009. J. Infect. 2010, 60:331-337.
5. Clancy C.J., Nguyen M.H. In vitro efficacy and fungicidal activity of voriconazole against Aspergillus and Fusarium species. Eur. J. Clin. Microbiol. Infect. Dis. 1998, 17:573-575.
6. De Pauw B., Walsh T.J., Donnelly J.P., Stevens D.A., Edwards J.E., Calandra T., Pappas P.G., Maertens J., Lortholary O., Kauffman C.A., Denning D.W., Patterson T.F., Maschmeyer G., Bille J., Dismukes W.E., Herbrecht R., Hope W.W., Kibbler C.C., Kullberg B.J., Marr K.A., Munoz P., Odds F.C., Perfect J.R., Restrepo A., Ruhnke M., Segal B.H., Sobel J.D., Sorrell T.C., Viscoli C., Wingard J.R., Zaoutis T., Bennett J.E. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin. Infect. Dis. 2008, 46:1813-1821.
7. Diaz Pedroche C., Cisneros J.M., Lumbreras C., Aguado J.M. Treatment of invasive fungal infections with voriconazole. Evaluation of experience with compassionate use of voriconazole in Spain. Rev. Esp. Quimioter. 2005, 18:149-158.
8. Dignani M.C., Anaissie E. Human fusariosis. Clin. Microbiol. Infect. 2004, 10(Suppl. 1):S67-S75.
9. Gonzalez G.M., Fothergill A.W., Sutton D.A., Rinaldi M.G., Loebenberg D. In vitro activities of new and established triazoles against opportunistic filamentous and dimorphic fungi. Med. Mycol. 2005, 43:281-284.
10. Guarro J., Gene J. Fusarium infections. Criteria for the identification of the responsible species. Mycoses 1992, 35:109-114.
11. Kontoyiannis D.P., Bodey G.P., Hanna H., Hachem R., Boktour M., Girgaway E., Mardani M., Raad I.I. Outcome determinants of fusariosis in a tertiary care cancer center: the impact of neutrophil recovery. Leuk. Lymphoma. 2004, 45:139-141.
12. Lewis R.E., Wiederhold N.P., Klepser M.E. In vitro pharmacodynamics of amphotericin B, itraconazole, and voriconazole against Aspergillus, Fusarium, and Scedosporium spp. Antimicrob. Agents Chemother. 2005, 49:945-951.
13. Liu K., Howell D.N., Perfect J.R., Schell W.A. Morphologic criteria for the preliminary identification of Fusarium, Paecilomyces, and Acremonium species by histopathology. Am. J. Clin. Pathol. 1998, 109:45-54.
14. Musa M.O., Al Eisa A., Halim M., Sahovic E., Gyger M., Chaudhri N., Al Mohareb F., Seth P., Aslam M., Aljurf M. The spectrum of Fusarium infection in immunocompromised patients with haematological malignancies and in non-immunocompromised patients: a single institution experience over 10 years. Br. J. Haematol. 2000, 108:544-548.
15. Nucci M., Anaissie E. Fusarium infections in immunocompromised patients. Clin. Microbiol. Rev. 2007, 20:695-704.
16. Nucci M., Anaissie E.J., Queiroz-Telles F., Martins C.A., Trabasso P., Solza C., Mangini C., Simoes B.P., Colombo A.L., Vaz J., Levy C.E., Costa S., Moreira V.A., Oliveira J.S., Paraguay N., Duboc G., Voltarelli J.C., Maiolino A., Pasquini R., Souza C.A. Outcome predictors of 84 patients with hematologic malignancies and Fusarium infection. Cancer 2003, 98:315-319.
17. Nucci M., Marr K.A., Queiroz-Telles F., Martins C.A., Trabasso P., Costa S., Voltarelli J.C., Colombo A.L., Imhof A., Pasquini R., Maiolino A., Souza C.A., Anaissie E. Fusarium infection in hematopoietic stem cell transplant recipients. Clin. Infect. Dis. 2004, 38:1237-1242.
18. Perfect J.R. Treatment of non-Aspergillus moulds in immunocompromised patients, with amphotericin B lipid complex. Clin. Infect. Dis. 2005, 40(Suppl. 6):S401-S408.
19. Perfect J.R., Marr K.A., Walsh T.J., Greenberg R.N., DuPont B., de la Torre-Cisneros J., Just-Nubling G., Schlamm H.T., Lutsar I., Espinel-Ingroff A., Johnson E. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin. Infect. Dis. 2003, 36:1122-1131.
20. Stanzani M., Tumietto F., Vianelli N., Baccarani M. Update on the treatment of disseminated fusariosis: Focus on voriconazole. Ther. Clin. Risk Manag. 2007, 3:1165-1173.